Anti-inflammatory agent-123
Anti-inflammatory agent-123 is an anti-inflammatory agent. Anti-inflammatory agent-123 inhibits NF-κB signaling pathway activation and the secretion of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Anti-inflammatory agent-123 inhibits NO production. Anti-inflammatory agent-123 can be used for inflammation research.
For research use only. We do not sell to patients.
- Formula: C23H16N2O
- Molecular Weight:336.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IL-6 |
IL-1β |
In Vitro
Anti-inflammatory agent-123 (Compound 3h) (5-20 μM; 2 h) effectively inhibits LPS-induced NO production in RAW264.7 cells, with an inhibition rate of 95.37% at 20 μM[1].
Anti-inflammatory agent-123 (5 μM; 2 h) inhibits NF-κB protein expression in LPS-stimulated RAW264.7 cells at 5 μM[1].
Anti-inflammatory agent-123 (50 μM; 24 h) does not exhibit significant cytotoxicity in RAW264.7 cells at 50 μM[1].
Anti-inflammatory agent-123 (10 μM) inhibits the production of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 in LPS-induced RAW264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 mouse mononuclear macrophage cells
-
Concentration:50 μM
-
Incubation Time:24 h
-
Result:Showed no significant cytotoxicity at 50 μM, with cell viability exceeding 80%.
-
Cell Line:RAW264.7 mouse mononuclear macrophage cells
-
Concentration:5 μM
-
Incubation Time:2 h (pre-incubation); 6 h (LPS treatment)
-
Result:Suppressed the activation of NF-κB in LPS-induced RAW264.7 cells.
Chemical Information
-
Molecular Weight 336.39
-
Formula C23H16N2O
-
SMILES
CC1=CC=C(N=C(C(C2=CC=CC=C2)=O)C3=C4NC5=C3C=CC=C5)C4=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Protocol for Phospho-flow cytometry
Phospho-flow cytometry detects intracellular phosphorylated signaling proteins in single cells using phospho-specific antibodies after rapid fixation and permeabilization; the fluorescence intensity reflects phosphorylation state and therefore kinase-pathway activation, inhibition, or drug response in defined cell subsets. Unlike Western blot, phospho-flow preserves single-cell resolution and can measure signaling heterogeneity in cancer cells, primary immune cells, dissociated mouse tumors, macrophages, organoid-derived cells, and drug-screening samples when validated antibodies and fixation/permeabilization conditions are used.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)